(AYTU) Aytu BioPharma, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AYTU) Aytu BioPharma, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Aytu BioPharma, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Adzenys XR-ODT 6+
Adzenys XR-ODT 6+ is a branded amphetamine orally disintegrating tablet for ADHD, labeled for patients 6 years and older. In Aytu BioPharma, Inc.’s BCG Matrix, it fits Stars because pediatric and adolescent ADHD still represents a large, durable prescription pool, and this brand remains one of the company’s clearest growth assets.
Cotempla XR-ODT 6-17
Cotempla XR-ODT is a methylphenidate extended-release orally disintegrating tablet for children and adolescents ages 6 to 17, so it targets a core ADHD segment. The CDC said 11.4% of U.S. children ages 3 to 17 had ever been diagnosed with ADHD in 2022, supporting steady demand. Its age-specific fit and easy ODT use give Aytu BioPharma, Inc. direct exposure to a large treatment pool.
Adzenys ER 6+
Adzenys ER 6+ is Aytu BioPharma, Inc.’s extended-release amphetamine oral suspension for ADHD, approved for patients aged 6 years and older. The liquid format helps when tablets or capsules are hard to use, which can lift access in pediatric care. In a market where about 7.1 million U.S. children ages 3-17 have an ADHD diagnosis, this product fits the "Star" profile if growth and share stay strong.
ADHD branded stimulant portfolio 3 products
Aytu BioPharma, Inc.'s ADHD branded stimulant portfolio has 3 products: Adzenys XR-ODT, Cotempla XR-ODT, and Adzenys ER. In the latest FY2025 context, that single-focus set targets the same pediatric and adolescent prescription niche, so ADHD remains the company’s clearest growth driver and the strongest "Stars" fit in the BCG Matrix.
- 3 brands, 1 core market
- Same high-need pediatric segment
- Growth-led, not diversified
Pediatric ADHD treatment market
Pediatric ADHD is a recurring prescription market because diagnosis and refill demand keep repeating through childhood, so it has the clearest Star-like profile in Aytu BioPharma, Inc.'s portfolio. Aytu sells across multiple dosage forms, which helps it serve different age and adherence needs. In the U.S., about 7 million children aged 3-17 have ADHD, keeping the addressable base large and steady.
- Recurring diagnoses support repeat scripts
- Multiple dosage forms widen access
- Largest BCG Star exposure for Aytu BioPharma, Inc.
Aytu’s ADHD Brands Tap a Huge, Recurring Pediatric Market
Aytu BioPharma, Inc.'s Stars are its ADHD brands: Adzenys XR-ODT, Cotempla XR-ODT, and Adzenys ER. In FY2025, they stayed tied to a large U.S. pediatric ADHD pool of about 7.1 million children ages 3 to 17, which keeps demand recurring and growth-linked. Their ODT and liquid formats help win use across age and adherence needs.
| Star asset | Core fit | Why it matters |
|---|---|---|
| Adzenys XR-ODT, Cotempla XR-ODT, Adzenys ER | Pediatric ADHD | Large repeat prescription base |
What is included in the product
Detailed Word Document
Aytu BioPharma BCG Matrix maps products by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
Clean BCG Matrix for Aytu BioPharma, Inc. that quickly clarifies portfolio priorities and pain points
Reference Sources
Provides a credible reference trail for Aytu BioPharma, helping users verify claims fast and support better decisions.
Cash Cows
Poly-Vi-Flor
Poly-Vi-Flor fits a Cash Cow profile: it is a prescription fluoride vitamin for infants and children, so demand is recurring and tied to routine pediatric care, not a fast product cycle. In Aytu BioPharma’s 2025 fiscal year, the brand supported steady prescription refill economics, which matters more than launch growth in a mature market.
Tri-Vi-Flor
Tri-Vi-Flor is a prescription vitamin supplement with fluoride for infants and children, so it fits Aytu BioPharma's cash-cow profile: steady demand, low price pressure, and limited promo spend. In a stable pediatric support niche, it can keep sales recurring even when growth is slow.
That kind of low-volatility revenue matters for funding newer products and protecting cash flow.
Karbinal ER
Karbinal ER is an oral carbinoxamine suspension for seasonal and perennial allergies, with a familiar repeat-use market and steady demand. Aytu BioPharma keeps it in the cash cow bucket because allergy care is recurring, not a fast-growth space. The product is sold as a 4 mg/5 mL ER suspension, which supports stable, lower-volatility sales.
Pediatric fluoride vitamin franchise
Aytu BioPharma’s pediatric fluoride vitamin franchise fits the Cash Cows box because it serves infants and children in a steady, recurring need market that is already mature. These products are usually low-complexity to make and sell, so Aytu can keep the line running with limited new investment while still pulling cash from existing demand. That makes it a maintenance business, not a growth engine.
- Steady pediatric demand
- Low reinvestment need
- Cash flow focus
Allergy suspension franchise
Karbinal ER anchors Aytu BioPharma, Inc.’s allergy suspension line, and the business fits a cash-cow profile: mature, established, and still pulled by repeat need. Allergic rhinitis affects about 81 million people in the U.S. each year, so seasonal and perennial demand keeps the category active beyond one peak season.
- Anchored by Karbinal ER
- Repeat allergy demand
- Mature, low-growth profile
- Cash cow, not a star
Aytu’s Cash Cows: Stable, Repeat-Use Revenue Drivers
Aytu BioPharma, Inc.’s cash cows are its mature pediatric fluoride vitamins and Karbinal ER. In fiscal 2025, these products fit a low-growth, repeat-use model that supports recurring cash flow more than new expansion. That makes them useful for funding other lines.
| Product | 2025 fit |
|---|---|
| Poly-Vi-Flor | Recurring pediatric demand |
| Tri-Vi-Flor | Stable refill base |
| Karbinal ER | Repeat allergy use |
Preview Before You Purchase
Aytu BioPharma, Inc. Reference Sources
The Aytu BioPharma, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. It comes as a fully formatted, ready-to-use report with no demo content or placeholders. Once purchased, you’ll get the complete file for immediate download and practical use. What you preview is what you own.
Dogs
Tuzistra XR
Tuzistra XR is a prescription cough syrup with codeine polistirex and chlorpheniramine polistirex, but it sits in a crowded, mature cough-and-cold market with low-single-digit growth. For Aytu BioPharma, Inc., it fits the Dogs bucket because it has limited expansion upside versus the ADHD portfolio. Its value is more defensive than growth-led.
ZolpiMist
ZolpiMist is a niche oral spray for insomnia, but sleep aids sit in a crowded, substitution-heavy market where pills, gummies, and generic zolpidem compete hard. Aytu BioPharma did not separately disclose ZolpiMist revenue in its latest FY2025 reporting, which limits proof of scale. With weak visible momentum and no clear cost edge, it fits best as a Dogs asset.
Cough suppressant line
Tuzistra XR is Aytu BioPharma, Inc.’s main cough-focused branded asset, but the cough market is mature and crowded, so growth stays weak. That makes this a Dogs-type business line in the BCG Matrix, with limited pricing power and thin portfolio economics. In this category, sales depend more on defending share than expanding demand.
Insomnia spray line
ZolpiMist is Aytu BioPharma, Inc.'s insomnia-focused branded asset, but it sits in a crowded sleep market where about 25% of U.S. adults report insomnia symptoms each year. With many drug and non-drug options, its niche scale and likely low share fit a dog in the BCG Matrix.
- ZolpiMist = niche insomnia brand.
- Crowded category limits growth.
- Low share points to dog.
Legacy symptom-relief brands
Aytu BioPharma’s legacy symptom-relief brands are mature, low-growth assets that can soak up management time without moving the needle much. In contrast, its pediatric ADHD products are the clearer growth driver, so these older non-ADHD lines fit a Dogs view in the BCG Matrix.
- Older brands, limited upside
- More support burden than growth
- ADHD drugs remain the focus
Tuzistra XR and ZolpiMist: Low-Growth Dogs, Not Growth Engines
Tuzistra XR and ZolpiMist stay in Aytu BioPharma, Inc.’s Dogs bucket because both sit in crowded, low-growth niches with limited scale. Aytu BioPharma, Inc. did not separately disclose ZolpiMist FY2025 revenue, which weakens proof of momentum. These brands look more like cash-preservation assets than growth drivers.
| Asset | FY2025 signal | BCG view |
|---|---|---|
| Tuzistra XR | Mature cough market | Dog |
| ZolpiMist | No separate FY2025 revenue | Dog |
Question Marks
International markets
Aytu BioPharma, Inc. serves both U.S. and international customers, but the non-U.S. market still has unclear scale and share, so it fits the Question Mark box. In FY2025, management did not show a clear global leadership position, and international growth remains more opportunity than proof. That makes this a high-upside, high-uncertainty expansion area.
Label expansion opportunities
Aytu BioPharma, Inc.'s ADHD portfolio already reaches children aged 6+ and 6-17, so label expansion could widen the addressable market if regulators approve broader age or usage claims. The upside is still uncertain because gains depend on FDA approval, physician uptake, and payer coverage, not just current demand. Until new labels land, this stays a Question Mark in the BCG Matrix.
Acquisition-led product additions
Aytu BioPharma, Inc., founded in 2015, has built around commercial products, so acquisition-led additions can expand brands or channels fast. The upside is real, but it depends on buying the right asset at the right price and integrating it well.
In a BCG Matrix lens, these moves can turn Question Marks into Stars only if growth beats the cash needed to scale. If the acquired product brings weak margins or slow adoption, the value case fades quickly.
Consumer health extensions
Aytu BioPharma, Inc. also frames itself as a consumer health player, so adjacent products could lift revenue beyond prescription drugs. But at end-2025, these extensions still look like a Question Mark in the BCG Matrix because their market share and profit pool are not yet clear.
That means the upside is real, but so is the risk: new SKUs need evidence of pull-through, repeat buys, and distribution scale before they can move out of the low-share, high-uncertainty zone.
- Adjacency can broaden revenue
- 2025 market position still unclear
- Execution will decide scale
Distribution and channel expansion
Aytu BioPharma, Inc. still sells through specialty and pediatric channels, so wider placement can lift unit volume if prescribers keep adopting the products. But with share still unclear and scale still limited versus larger pharma peers, this fits a question mark: growth is possible, yet not proven.
- Specialty and pediatric focus supports targeted demand
- Broader placement can expand volume fast
- Market share is still too uncertain
Aytu’s 2025 Growth Bets: Big Upside, Still Unproven
Aytu BioPharma, Inc. stays a Question Mark because its 2025 international scale, ADHD label expansion, and acquisition-led growth are still unproven. The upside is real, but share, payer access, and physician uptake are not yet clear. Execution will decide whether these bets turn into Stars or stay low-share, high-uncertainty moves.
| Factor | 2025 view |
|---|---|
| International reach | Unclear scale |
| ADHD expansion | Pending approval |
| Acquisitions | Opportunity, not proof |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.